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Abstract
Umbilical cord blood (UCB) has been increasingly used as a source of haematopoietic
stem cells (HSCs) for transplantation. UCB transplantation (UCBT) has some advan‐
tages such as less stringent human leucocyte antigen (HLA) matching and lower impact
of  graft‐versus‐host  disease (GvHD).  UCBT is  also characterised by a high rate of
infections, graft failure, delayed engraftment and slow recovery of the immune system.
UCB contains HSC as well as immune cells that could be considered to develop new
treatments for the main complications post‐UCBT but also to treat other diseases. GvHD
remains a major complication post‐CBT and post‐haematopoietic stem cell transplan‐
tation (HSCT). In view of their ability to induce tolerance and suppress the functions of
effector T cells, regulatory T (Treg) cells have been proposed as an adoptive therapy to
modulate GvHD post‐HSCT. In addition, we showed that UCB contains soluble NKG2D
ligands that  can modulate the functions of  NKG2D expressing cells,  making UCB
plasma a product of interest to modulate inflammation and in particular skin GvHD.
Here, we aim to describe some of the therapies currently developed using UCB, focusing
on Treg cells and UCB plasma for the treatment of GvHD.
Keywords: umbilical cord blood, plasma, regulatory T cells, graft versus host disease,
immunotherapy
1. Introduction
Haematopoietic stem cell transplantation (HSCT) is currently used to treat many bone marrow
and blood disorders as well as malignancies and has become either an established life‐saving
treatment or a life‐sustaining option for many patients. However, even nowadays, HSCT has
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a high treatment‐related mortality, as only half of the patients that receive a transplant will
survive the procedure. This high mortality is due to major complications such as relapse, graft
failure, delayed immune reconstitution, opportunistic infections and graft‐versus‐host disease
(GvHD).
After allogeneic HSCT, donor natural killer (NK) cells and T cells can attack the allogeneic
tumour in a phenomenon described as graft versus leukaemia (GvL), which is the beneficial
aspect of tissue disparity. However, allografts contain lymphocytes able to recognise and
respond against host antigens and cause potentially life‐threatening GvHD affecting internal
organs and systems. In addition, GvHD can affect the skin and eyes and can be very painful
and distressing for the patient, thus impacting on the patient quality of life especially in the
case of chronic GvHD. Moreover, GvHD increases the risk of a variety of bacterial, viral and
fungal infections [1].
Hal Broxmeyer proposed the use of umbilical cord blood (UCB) as a source of haematopoietic
stem cells (HSCs) for transplantation in 1982. The first umbilical cord blood transplantation
(CBT) was performed for the first time in 1988 to treat a patient with Fanconi’s anaemia [2].
Since then, UCB has been increasingly used as a source of HSC extending the availability of
allogeneic HSCT to patients who would not have a matched donor. UCB has some advantages
over the use of other grafts such as faster availability, less stringent human leucocyte antigen
(HLA) matching, decreased incidence and severity of GvHD. However, patients who receive
a UCB transplant are at higher risk of graft failure, infection and delayed engraftment and
immune reconstitution. In addition, the use of UCB is restricted by the number of cells it
contains, in particular of HSC, and it does not offer the option of a donor lymphocyte infusion
if needed.
However, UCB does not only contain HSC enabling transplant but also contains immune cells
such as regulatory T (Treg) cells and numerous proteins involved in inducing tolerance during
pregnancy to prevent foetal rejection. Therefore, UCB is a unique resource that could also be
used in order to develop immunotherapeutic approaches to counteract complications post‐
HSCT including post‐UCBT. This chapter focuses on the latest studies and immunotherapeutic
approaches relating to the use of UCB to treat GvHD post‐HSCT.
2. Umbilical cord blood-derived therapies to modulate GVHD
2.1. Use of umbilical cord blood plasma for immunotherapy
In human pregnancy, immunological tolerance of the unborn foetus by the maternal immune
system is essential. Without such mechanisms, the foetus would be readily ‘rejected’ as genetic
differences arising from paternal HLA would elicit an immune response in a similar manner
to a haplo‐identical (50% match) transplant. Since this concept was postulated by Sir Peter
Medawar in the 1950s, researchers have attempted to identify these mechanisms, not only to
better understand pregnancy and pregnancy complications but also to allow tolerance of
transplanted tissues such as kidneys, hearts or BM in the context of HSCT.
Umbilical Cord Blood Banking for Clinical Application and Regenerative Medicine170
The immune system of the unborn foetus is immature yet capable of defence against certain
pathogens and therefore mechanisms of tolerance towards the genetically disparate maternal
host must also play a role in successful pregnancy. This concept is less well understood but
advances are now being made following the use of UCB as a source of HSC for transplantation.
The neonatal immune system is biased towards a Th2‐type regulatory immune response rather
than a pro‐inflammatory Th1 response, affecting acquired and innate cellular responses.
Evidence for this has been gained from experiments using UCB cells and also by the identifi‐
cation of immunosuppressive substances found in umbilical cord blood plasma (CBP). For
example, TGF‐β produced by Treg cells controls proliferation and differentiation of many
different cell types, including limiting cytotoxicity of natural killer (NK) cells, and is one of the
many immunosuppressive substances found in CBP.
Notably, we have recently identified a new mechanism of immunological tolerance reducing
NK cell cytotoxicity that is mediated by proteins found in CBP, called natural killer group 2
member D (NKG2D) ligands (NKG2DL) [3]. NKG2D is an activating receptor on NK and NKT
cells and a costimulatory receptor on CD8+ T cells. Unusually, two gene families known as the
MHC class I‐related chain A and B (MICA/B) and UL16‐binding proteins (ULBP1‐6) encode
the ligands for NKG2D. Furthermore, allelic polymorphism of these genes, in particular MICA
and MICB, creates a uniquely diverse range of NKG2D ligands (NKG2DL) that can vary
between individuals. Upregulation of NKG2DL on cells and tissues occurs in situations of
‘stress’ such as viral infection or oncogenic transformation, leading to cytolysis by NK cells or
other NKG2D‐bearing cells.
However, NKG2DL appear to have dual opposite roles as soluble NKG2DL engagement with
NKG2D causes downregulation of this receptor with concomitant suppression of NK cell
activation and proliferative potential, decreased cytolytic activity (degranulation) and reduced
interferon‐gamma (IFN‐γ) production. We found that compared with healthy adult plasma,
CBP contains significantly more soluble MICA, MICB and ULBP1 ligands. CBP affected
degranulation, cytotoxicity and cytokine production of NK cells. We confirmed these results
by physical removal of NKG2DL, where function was partially restored. In addition, blocking
of NKG2D prior to the K562 killing assay mostly prevented K562 lysis, showing that NKG2D
interaction was the main mechanism involved.
The immunosuppressive capacity of CBP and its effects on NK cells and T cells may offer
potentially powerful therapeutic applications for diseases that have previously been difficult
to treat successfully. In the case of GvHD post‐HSCT, the cytokines produced by alloreactive
T cells may prime NK cells and other innate immune cells, amplifying potential GvHD tissue
damages. Despite attempts to manipulate the immune system before, during and after
transplantation, GvHD is still the prominent cause of morbidity and mortality following HSCT.
Here, we propose the use of CBP to treat local GvHD, initially focussing on local topical
application of CBP via creams and drops to alleviate dermatological or ocular problems, such
as chronic skin or eye GvHD. The immunosuppression of NK cells and T effector cells at the
skin surface or conjunctiva should prevent the damages caused by cytotoxicity of these cells
and alleviate symptoms, without causing further systemic immunosuppression.
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The same principles could also be applied for the treatment of other diseases of common
‘autoimmune‘ dermatological disorders (reviewed in: [4]) such as eczema, which affects large
numbers of people, especially children. Psoriasis is another candidate disease driven by
autoimmune skin inflammation and cytokine release that could be amenable to CBP immu‐
notherapy. Another, less common but nevertheless extremely distressing condition is alopecia
areata (AA), also known as spot baldness, and affects the scalp. This was also thought to be an
autoimmune disease mediated by T cells, but recent genomewide association data have
emerged directly implicating NK cell cytotoxicity as well as CD8+ NKG2D+ T cells against the
hair follicle. It was found that in normal hair follicles, expression of NKG2DL ULBP3 is turned
off. However in patients with AA, the follicles often express ULBP3 and are therefore vulner‐
able to attack via T‐cell costimulation and NK cell degranulation together with production of
high levels of pro‐inflammatory interferon gamma (IFNγ). In this situation, therapy with CBP
containing soluble NKG2DL could neutralise activation of effector cells and prevent destruc‐
tion of the hair follicles. Another area of interest for treatment using CBP is localised therapy
to alleviate symptoms of rheumatoid arthritis (RA). RA is a chronic autoimmune disease
characterised by joint inflammation, cartilage and bone, destruction and elevated levels of pro‐
inflammatory cytokines. The lymphocytes in synovial fluid of affected joints contain up to 25%
NK cells during early disease, the majority of which are CD56bright NK cells with high capacity
for cytokine secretion. Compared with peripheral CD56bright NK cells, synovial CD56bright NK
cells are more abundant and produce more TNFα and IFNγ, implicating these cells with
initiation and perpetuation of dysregulated pro‐inflammatory cytokine production [4]. We
found that CD56bright NK cells become hyporesponsive after treatment with CBP and produce
significantly less IFNγ, which could alter the pro‐inflammatory cytokine milieu and reduce
inflammation and the damage caused by RA.
In conclusion, CBP has the potential to treat a wide range of diseases that are mediated, at least
in part, by inappropriate NK cell activation and tissue destruction. The effect of soluble
NKG2DLs as immunosuppressive agents to limit NK cell activation as well as CD8+ T‐cell
costimulation is very powerful but also reversible by removing the source. However, it is still
unknown which type of NKG2DL is responsible or whether combinations of different ligands
are beneficial. We identified soluble ULBP1 in almost all and soluble MICB in the majority of
CBP samples, whereas soluble MICA was present in about one third. Although ULBP1 is not
polymorphic, soluble MICA and MICB ligands have considerable allelic polymorphism and
differing levels of expression. We are currently carrying out experiments to determine which
ligands mediate the effects and whether allelic polymorphism in promoter and expressed
domains also plays a role in order to optimise the selection of CBP for immunotherapy and
maximise the chances of therapeutic success.
2.2. Use of umbilical cord blood regulatory T cells for immunotherapy
Treg cells represent 5–10% of CD4+ T cells in humans and in mice and are characterised as
CD4+CD25highCD127lowFoxp3high [5]. Treg cells are key players in maintaining tolerance and
immune homeostasis and have been shown to inhibit the functions of various immune cells
such as CD4 and CD8 T cells [6, 7], B cells, and NK cells [8]. Treg cells can act directly by
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inhibiting the functions of target cells by releasing suppressive cytokines such as interleukin
(IL)‐10, transforming growth factor β (TGF‐β) or IL‐35, depleting the environment of IL‐2 [9–
12] or indirectly by interacting with antigen‐presenting cells (APCs) and regulating their
functions [13].
Because of their ability to induce tolerance and suppress the functions of effector T cells, Treg
cells have been proposed as a cell therapy to prevent or modulate GvHD post‐HSCT as a
supplement or replacement for conventional pharmacological immunosuppression. The
feasibility and safety of this therapy in transplanted patients has been demonstrated in
different phase I/II clinical trials using mainly PB Treg cells (see Table 1). Trzonkowski et al.
[14] showed that expanded Treg cells could control GvHD allowing withdrawal of steroid
treatment in transplanted patients. Di Ianni et al. [15] demonstrated that non expanded donor
Treg cells were able to counteract the potential GvHD that would otherwise be induced by the
infusion of a high number of effector T cells in haploidentical HSCT patients while positively
impacting on immune reconstitution. In addition, in the same haploidentical HSCT setting,
Martelli et al. [16] reported reduced relapse rates after infusion of non‐expanded donor Treg
cells. Edinger and Hermann [17] demonstrated the safety and feasibility of the administration
of expanded Treg cells in patients that presented high risk of leukaemia relapse. Finally, a recent
trial showed that the use of expanded Treg cells to modulate chronic GvHD led to reduced
immunosuppression post‐HSCT; however, tumours were detected in two patients [18].
Overall, although the use of Treg cells to modulate GvHD is very promising, it is clear that
more studies are needed in order to really understand the potential impact of a Treg cell therapy
on tumour and viral immunity post‐HSCT.
Centre Phase Cell dose Product Effects Ref
Gdansk I 1 × 105 to 3 × 106/kg Expanded Treg cells Safe, reduced immunosuppression [14]
Minnesota I 1–30 × 105/kg Expanded UCB Treg cells Safe, reduced acute GvHD, increased
infection
[26, 33]
Minnesota I 3–100 × 106/kg Expanded UCB Treg cells
with engineered cell line
Safe, reduced GVHD and no increased
relapse
[27]
Perugia I 2–4 × 106/kg Fresh Treg cells Safe, reduced leukaemia relapses,
reduced incidence of GvHD
[15, 16]
Regensburg I 5 × 106/kg Fresh Treg cells Safe [17]
Dresden I 0.6–5 × 106/kg Expanded Treg cells Tumours in 2 patients, stable chronic
GvHD
[18]
Table 1. List of clinical studies testing the use of Treg cells to treat or modulate GvHD.
In these trials, Treg cells were mainly isolated from PB sources; however, two trials were
performed using expanded Treg cells isolated from UCB. In fact, UCB is an attractive source
of Treg cells because of several features. The frequency of Treg cells is identical in PB and UCB
[5]. In addition, UCB has the advantage of being readily available as UCB can be obtained from
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accredited UCB banks, offering the possibility to develop an off-the-shelf therapy. Which
degree of matching should be used will need further evaluation in clinical studies, especially
as HLA matching is less stringent when considering UCB; trials using UCB Treg cells already
suggested that it is possible to use a 4/6 match for UCB Treg cells when considering a third-
party therapy. Furthermore, it is possible to purify Treg cells with high purity in one single
step as opposite to a two-step process when isolating PB Treg cells [19]. CB Treg cells comprise
almost entirely of a naïve T-cell phenotype CD45RA+ in contrast to the adult PB Treg cells than
have a central memory phenotype (CD62LhighCCR7highCD45RO+). As a consequence, UCB Treg
cells have a higher capacity to maintain Foxp3 expression, and a better suppressive capacity
and stability after expansion [20]. UCB Treg cells may have a survival advantage over PB Treg
cells as they have been shown to be more resistant to apoptosis than PB Treg cells [21]. Finally,
we and others have demonstrated Treg cells from UCB to be able to inhibit the function of
effector cells [19, 22, 23], while other groups have reported UCB Treg cells to have low
suppressive capacity [24, 25]. The required cell dose for clinical use is crucial and dictates the
practicality of the cell source considered and post-isolation manipulation if required.
In any case, whatever the cell source considered, only very few cells can be isolated from UCB
or PB; therefore, most groups have focused on developing strategy to expand UCB Treg cells
to enable cell therapy [26–28]. The majority of expansion protocols seek to expand Treg cells
and maintain their natural Treg (nTreg) cell phenotype. Multiple studies have reported
expanding nTreg cells from both PB and UCB [14, 26]. Recently, conditions to expand Treg cells
have become increasingly well defined and translated into GMP compliant protocols. The
majority of groups (see Table 1) use anti-CD3 antibody attached to beads in combination with
anti-CD28 for costimulation and supplemented with IL-2 ranging from 300 to 1000 IU/ml.
When expanding from PB Treg cells, rapamycin is often added to the expansion cultures,
sometimes in combination with retinoic acid both to prevent the outgrowth of effector T cells
and to promote Treg cell expansion, especially in the case of multiple restimulations [29]. With
UCB Treg cells, it is noticeable that rapamycin seems not so vital. Brunstein et al. used beads
or an engineered cell line in order to expand UCB Treg cells [26, 27]. This recently published
study used anti-CD3 antibody-loaded K562 cells modified to express the high-affinity Fc
receptor CD64 and the costimulatory ligand CD86 [27]. Using this culture condition, expansion
of up to 10,000 fold of UCB Treg cells was achieved.
Following expansion, Treg cells should as much as possible retain their nTreg cell phenotype
(CD3+CD4+CD127lowCD25+FOXP3+CD62LlowCCR7+). FOXP3+ expression would seem vital;
however, FOXP3 is also expressed on activated effector T cells and so in itself does not
distinguish between them. However, FOXP3 expression should be high and sustained. In
addition, Helios expression has been associated with natural Tregs, and its presence in
expanded cells is also an additional indication that the cells have retained an nTreg phenotype.
Expanded cells should be able to suppress the function of effector T cells in vitro. In addition,
stability of the FOXP3 expression should also be tested. The methylation state of the FOXP3
locus is indicative of recent chromosomal remodelling and thus distinguishes between FOXP3
expression being induced over constitutive expression in Treg cells [30]. The study of Treg cell
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development in the thymus indicates that the FOXP3 locus becomes demethylated during
development and indicates a stable commitment to the Treg cell lineage [31, 32].
Two phase I clinical trials using third‐party UCB Treg cells have reported the feasibility and
safety of infusing expanded UCB Treg cells in patients that received double UCBT (Table 1).
Brunstein et al. [26] showed reduced acute GvHD in this cohort of patients with increased
incidence of infection [33] and recently reported similar impact of expanded UCB Treg cells
on acute GvHD in another trial [27]. However, in both clinical studies Treg cells could only
persist for a maximum of 2 weeks in vivo. These results therefore also highlight that we need
to understand better the characteristics of expanded cells if we want these cells to persist for
longer in patients once infused.
We previously showed that Treg cells could be isolated from fresh UCB units using only the
marker CD25 and that the isolated Treg cells were able to suppress effector T cells in vitro [19].
However, this method led to variable purity and yield when isolating Treg cells from cryo‐
preserved UCB units. Therefore, within the T‐Control consortium (http://www.t‐control.info),
we focused our efforts on developing a method to isolate Treg cells from fresh or cryopreserved
UCB using the streptamer reversible technology. This method allows the purification of Treg
cells with good recovery and purity and offers the potential to have an off‐the‐shelf Treg cell
product as well as selecting UCB units for specific HLA types. In order to overcome the lack
of persistence of Treg cells in patients, we are planning to use this method to purify Treg cells
from cryopreserved UCB units as to obtain a minimally manipulated cell product that could
be tested in transplanted patients to control GvHD. However, we are also exploring the
possibility to expand streptamer isolated Treg cells from cryopreserved UCB units for immu‐
notherapy.
More studies are needed to really gain a better understanding of the characteristics of third‐
party UCB Treg cells in order to optimise their use as immunotherapy. Further preclinical and
clinical studies will help to identify the best conditions to activate and expand UCB Treg cells
for use in patients to treat GvHD but also to optimise their use as for PB Treg cells for other
conditions such as inhibiting graft failure after organ transplantation or to treat autoimmune
diseases such as arthritis or diabetes alone or together as a combined therapy with other
suppressive cells such as mesenchymal stem cells.
3. Conclusion
Immunotherapy has been a promising option in order to improve the outcome of HSCT. UCB‐
derived immunotherapies are very promising, and future studies will help us understanding
their potential better. UCB Treg cells could become an immunotherapy of choice for treating
GvHD. In addition, one should also consider the use of UCB plasma that already contains
proteins with the capacity to modulate the immune response in particular inflammation to
treat skin GvHD as well as autoimmune diseases.
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